These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
471 related articles for article (PubMed ID: 15356679)
1. Type IV collagenase (matrix metalloproteinase-2 and -9) in prostate cancer. Zhang L; Shi J; Feng J; Klocker H; Lee C; Zhang J Prostate Cancer Prostatic Dis; 2004; 7(4):327-32. PubMed ID: 15356679 [TBL] [Abstract][Full Text] [Related]
2. Expression of matrix metalloproteinase-2 and -9 and their inhibitors, tissue inhibitor of metalloproteinase-1 and -2, in primary cultures of human prostatic stromal and epithelial cells. Wilson MJ; Sellers RG; Wiehr C; Melamud O; Pei D; Peehl DM J Cell Physiol; 2002 May; 191(2):208-16. PubMed ID: 12064464 [TBL] [Abstract][Full Text] [Related]
3. [Expression of matrix metalloproteinases-9,2,7,and tissue inhibitor of metalloproteinases-1,2,3 mRNA in ovarian tumors and their clinical significance]. Hu XX; Li L; Li DR; Zhang W; Cheng XQ; Zhang JQ; Tang BJ Ai Zheng; 2004 Oct; 23(10):1194-8. PubMed ID: 15473934 [TBL] [Abstract][Full Text] [Related]
4. Elevated activities of MMP-2 in the non-tumorous lung tissues of curatively resected stage I NSCLC patients are associated with tumor recurrence and a poor survival. Kim SH; Choi HY; Lee J; Son DS; Lee HS; Song IS; Lim YS; Hong YS; Kim J; Choi YS J Surg Oncol; 2007 Mar; 95(4):337-46. PubMed ID: 17326127 [TBL] [Abstract][Full Text] [Related]
5. Expression of matrix metalloproteinase-7 and tissue inhibitor of metalloproteinase-1 in human prostate. Hashimoto K; Kihira Y; Matuo Y; Usui T J Urol; 1998 Nov; 160(5):1872-6. PubMed ID: 9783977 [TBL] [Abstract][Full Text] [Related]
6. CD147, MMP-1, MMP-2 and MMP-9 protein expression as significant prognostic factors in human prostate cancer. Zhong WD; Han ZD; He HC; Bi XC; Dai QS; Zhu G; Ye YK; Liang YX; Qin WJ; Zhang Z; Zeng GH; Chen ZN Oncology; 2008; 75(3-4):230-6. PubMed ID: 18852494 [TBL] [Abstract][Full Text] [Related]
7. Clinical significance of matrix metalloproteinase-2 in cancer of uterine cervix: a semiquantitative study of immunoreactivities using tissue array. Wang PH; Ko JL; Tsai HT; Yang SF; Han CP; Lin LY; Chen GD Gynecol Oncol; 2008 Mar; 108(3):533-42. PubMed ID: 18177928 [TBL] [Abstract][Full Text] [Related]
8. Expression of latent matrix metalloproteinase 9 (MMP-9) predicts survival in advanced ovarian cancer. Lengyel E; Schmalfeldt B; Konik E; Späthe K; Härting K; Fenn A; Berger U; Fridman R; Schmitt M; Prechtel D; Kuhn W Gynecol Oncol; 2001 Aug; 82(2):291-8. PubMed ID: 11531282 [TBL] [Abstract][Full Text] [Related]
9. Evidence for increased activated metalloproteinase 2 (MMP-2a) expression associated with human prostate cancer progression. Stearns M; Stearns ME Oncol Res; 1996; 8(2):69-75. PubMed ID: 8859777 [TBL] [Abstract][Full Text] [Related]
10. Quantitative immunohistochemical and in situ hybridization analysis of metalloproteinases in prostate cancer. Cardillo MR; Di Silverio F; Gentile V Anticancer Res; 2006; 26(2A):973-82. PubMed ID: 16619495 [TBL] [Abstract][Full Text] [Related]
11. High serum levels of matrix metalloproteinase-9 and matrix metalloproteinase-1 are associated with rapid progression in patients with metastatic melanoma. Nikkola J; Vihinen P; Vuoristo MS; Kellokumpu-Lehtinen P; Kähäri VM; Pyrhönen S Clin Cancer Res; 2005 Jul; 11(14):5158-66. PubMed ID: 16033831 [TBL] [Abstract][Full Text] [Related]
12. [Zymography--method for quantitation of activity on gelatinase A (pro-MMP-2, 72 kDa) and gelatinase B (pro-MMP-9, 92 kDa) in serum of patients with breast cancer]. Sliwowska I; Kopczyński Z Wiad Lek; 2007; 60(5-6):241-7. PubMed ID: 17966888 [TBL] [Abstract][Full Text] [Related]
13. Clinical significance of matrix metalloproteinase 2 and 9 in breast cancer. Shah FD; Shukla SN; Shah PM; Shukla HK; Patel PS Indian J Cancer; 2009; 46(3):194-202. PubMed ID: 19574670 [TBL] [Abstract][Full Text] [Related]
14. [Expression of MMP-2, MMP-9 and collagen type IV and their relationship in colorectal carcinomas]. Wu W; He JT; Ruan JD; Wang RB; Zhang YD Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2008 Sep; 24(9):908-9. PubMed ID: 18782525 [TBL] [Abstract][Full Text] [Related]
15. Activation of MMP-2 and MMP-9 in patients with oral squamous cell carcinoma. Patel BP; Shah PM; Rawal UM; Desai AA; Shah SV; Rawal RM; Patel PS J Surg Oncol; 2005 May; 90(2):81-8. PubMed ID: 15844188 [TBL] [Abstract][Full Text] [Related]
16. Quantitative estimation of matrix metalloproteinases 2 and 7 (MMP-2, MMP-7) and tissue inhibitors of matrix metalloproteinases 1 and 2 (TIMP-1, TIMP-2) in colorectal carcinoma tissue samples. Pesta M; Holubec L; Topolcan O; Cerna M; Rupert K; Holubec LS; Treska V; Kormunda S; Elgrova L; Finek J; Cerny R Anticancer Res; 2005; 25(5):3387-91. PubMed ID: 16101153 [TBL] [Abstract][Full Text] [Related]
17. Regulation of matrix metalloproteinase 13 expression by androgen in prostate cancer. Pang ST; Flores-Morales A; Skoog L; Chuan YC; Nordstedt G; Pousette A Oncol Rep; 2004 Jun; 11(6):1187-92. PubMed ID: 15138554 [TBL] [Abstract][Full Text] [Related]
18. Differential expression of E-cadherin and type IV collagenase genes predicts outcome in patients with stage I non-small cell lung carcinoma. Herbst RS; Yano S; Kuniyasu H; Khuri FR; Bucana CD; Guo F; Liu D; Kemp B; Lee JJ; Hong WK; Fidler IJ Clin Cancer Res; 2000 Mar; 6(3):790-7. PubMed ID: 10741698 [TBL] [Abstract][Full Text] [Related]
19. The role of prostate specific membrane antigen and pepsinogen C tissue expression as an adjunctive method to prostate cancer diagnosis. Antunes AA; Leite KR; Sousa-Canavez JM; Camara-Lopes LH; Srougi M J Urol; 2009 Feb; 181(2):594-600. PubMed ID: 19084862 [TBL] [Abstract][Full Text] [Related]
20. Expression of matrix metalloproteinase 2 and its tissue inhibitor in oral squamous cell carcinoma. Gao ZB; Duan YQ; Zhang L; Chen DW; Ding PT Int J Mol Med; 2005 Oct; 16(4):599-603. PubMed ID: 16142392 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]